Compare Gilead Sciences, Inc. (GILD) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Marathon Digital Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Marathon Digital Holdings Inc trades at $11.45 (market cap $4.69B). The key difference: Gilead Sciences, Inc. is far larger — about 34.9× Marathon Digital Holdings Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.
| GILD | MARA | |
|---|---|---|
Market Cap | $163.51B | $4.69B |
Sector | Health | Technology |
52-Week High | $155.80 | $22.84 |
52-Week Low | $108.22 | $6.73 |
Enterprise Value | $178.05B | $6.64B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MARA stock trades at $11.74, down 3.45% today, amid a bearish technical trend and negative earnings momentum with three consecutive quarterly misses. The company reported a net loss of $1.31B on $907M revenue in 2025, though analyst sentiment remains mixed with a 50% buy rating and $17.88 consensus price target. Recent news highlights MARA's pivot to AI infrastructure, including a Texas land acquisition adding 2 GW power capacity (GlobeNewsWire, July 9, 2026).
The outlook balances strategic growth in AI against persistent profitability challenges. Investment opportunity lies in the AI pivot potentially driving future revenue, but risks include high cash burn, negative margins, and execution uncertainty. The stock's current valuation multiples suggest discount, but sustained losses warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
